Glioblastoma multiforme (GBM) and primary central nervous system lymphoma (PCNSL) are both malignant cerebral tumors; however, their treatments are vastly different. Early and precise diagnosis is vital for subsequent adequate treatment to improve prognosis. Reliable biomarkers that can easily distinguish GBM and PCNSL are urgently needed. We evaluated the diagnostic potential of lymphocyte‐specific protein tyrosine kinase (LCK) as a biomarker in differentiating PCNSL from GBM using established computational approaches (Gene Expression Profiling Interactive Analysis, The Cancer Proteome Atlas, Tumor Immune Estimation Resource, GEO, Oncomine) and immunohistochemistry. The results showed that LCK was expressed at a high level in PCNSL patients but at a low level in GBM patients. Moreover, LCK expression positively correlated with the levels of infiltrating B cells in diffuse large B‐cell lymphoma (DLBCL) and GBM. Overall, bioinformatics analysis and immunohistochemistry revealed that LCK expression is a potential biomarker for distinguishing PCNSL from GBM.

中文翻译：

---

LCK表达是区分原发性中枢神经系统淋巴瘤和胶质母细胞瘤的潜在生物标志物。

多形性胶质母细胞瘤（GBM）和原发性中枢神经系统淋巴瘤（PCNSL）均为恶性脑肿瘤。但是，它们的处理方式大不相同。早期和精确的诊断对于随后的适当治疗以改善预后至关重要。迫切需要能够轻松区分GBM和PCNSL的可靠生物标志物。我们使用建立的计算方法（基因表达谱分析，癌症蛋白质组图谱，肿瘤免疫估计资源，GEO，Oncomine）和免疫组化方法评估了淋巴细胞特异性蛋白酪氨酸激酶（LCK）作为生物标志物在将PCNSL与GBM区分中的诊断潜力。 。结果表明，LCK在PCNSL患者中高水平表达，而在GBM患者中低水平表达。此外，LCK表达与弥漫性大B细胞淋巴瘤（DLBCL）和GBM中浸润的B细胞水平呈正相关。总体而言，生物信息学分析和免疫组化显示，LCK表达是区分PCNSL和GBM的潜在生物标记。